Certainty was rated as moderate that PDE5 inhibitors probably improve erectile function in men with MS, while certainty was low for any effect on broader sexual satisfaction, relationship outcomes, or female SD because of sparse data [51,53,57,58,59,73]. Here, PDE5A is linked to myeloid sarcoma.